A new market study, titled “Global Anti-Hypertensive Drugs Market Research Report- Forecast to 2022” has been featured on WiseGuyReports.
This report analyzes the global anti-hypertensive drugs market by Pharmacological Class (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker, etc.), by Hypertension Type (Systemic and Pulmonary Hypertension Drugs), by Disease Source (Primary and Secondary) and region; it also studies the top manufacturers in the market.
The global anti-hypertensive drugs market was valued at $32.2 billion in 2015, and is predicted to reach $ 38.9 billion by 2022. Thus the market is anticipated to accomplish slow growth at a CAGR of 2.73% from 2016 till 2022.
The major players in global anti-hypertensive drugs market include:
- Novartis AG
- Daiichi Sankyo Company Limited
- Actelion Ltd
- Boehringer Ingelheim
- Sanofi S.A.
- Astra Zeneca plc
- Ranbaxy Laboratories Limited, Inc.
- Takeda Pharmaceuticals Company Limited
- Pfizer Inc.
The market revenue and share have been analyzed with respect to the following regions and countries:
Rest Of Europe
Republic Of Korea
Rest of Asia-Pacific
Middle East & Africa
On the basis of pharmacological class, the global anti-hypertensive drugs market has been categorized into the following segments:
- ACE Inhibitors
- Calcium Channel Blockers
- Beta – Adrenergic Blocker
- Alpha – Adrenergic Blocker
- Central Sympatholytic
- Renin Inhibitors
On the basis of hypertension type, the global anti-hypertensive drugs market has been categorized into the following segments:
- Systemic Hypertension Drugs
- Pulmonary Hypertension Drugs
On the basis of disease source, the global anti-hypertensive drugs market has been categorized into the following segments:
- Primary Or Essential Hypertension
- Secondary Hypertension
Market Research Future analysis is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, competitive landscape (CL), and market penetration, as well as on emerging trends. Besides primary interviews (~80%) and secondary research (~20%), their analysis is based on years of professional expertise in their respective industries. Our analysts also predict where the market will be headed in the next five to 10 years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories in different regions are estimated based on primary and secondary research.
Both the top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent sub-markets. The key players in the market were identified through secondary research, and their market contributions in the respective regions were determined through primary and secondary research. This entire process included the study of the annual and financial reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to arrive at the final quantitative and qualitative data. This data has been consolidated, and detailed inputs and analysis by Market Research Future added before being presented in this report.
Table of Content
2 Research Methodology
3 Market Dynamics
4 Market Factor Analysis
5 Global Anti-Hypertensive Drugs Market, By Pharmacological Class
6 Global Anti-Hypertensive Drugs Market, By Hypertension Type
7 Global Anti-Hypertensive Drugs Market, By Disease Source
8 Global Anti-Hypertensive Drugs Market, By Regions
9 Company Landscape
10 Company Profile
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)